Original Research

Open Clinical Trials for Native Americans With Diabetes Mellitus


 

Providing access to clinical trials for patients with diabetes mellitus can be a challenge, but a significant number of trials are now recruiting patients. The clinical trials listed below are all open as of October 31, 2019; and are focused on diabetes mellitus-related treatments for American Indians. For additional information and full inclusion/exclusion criteria, please consult clinicaltrials.gov.

Cross-Sectional and Longitudinal Studies of “Pre-Diabetes” in the Pima Indians

The Pima Indians of Arizona have the highest prevalence and incidence of type 2 diabetes of any population in the world. Prospective analyses in this population have identified insulin resistance and a defect in early insulin secretion as risk factors for the development of the disease. To identify the genetic and environmental determinants of diabetes we plan to study Pima Indian families to determine: (1) if there are genes that segregate with metabolic risk factors for diabetes which might therefore be genetic markers for type 2 diabetes; and (2) the mechanisms mediating genetic and environmental determinants of insulin resistance and impaired insulin secretion.

ID: NCT00340132
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact: Clifton Bogardus, MD, cbogardus@phx.niddk.nih.gov
Location: NIDDK, Phoenix, AZ


Empaglifozin in Early Diabetic Kidney Disease

Diabetes is common among American Indian people and diabetic kidney disease is a common complication. Kidney disease caused by diabetes can lead to the need for kidney replacement, by dialysis or kidney transplant, and is also associated with higher risk of early death. A new diabetes medicine called empagliflozin may slow kidney disease from type 2 diabetes. Researchers want to learn if it protects the kidneys when used in very early stages of diabetic kidney disease.

ID: NCT03173963
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact: Helen C Looker, helen.looker@nih.gov
Location: NIDDK, Phoenix, AZ


Family Investigation of Nephropathy and Diabetes

The Family Investigation of Nephropathy and Diabetes (FIND) is a multicenter study designed to identify genetic determinants of diabetic kidney disease. FIND will be conducted in 11 centers and in many ethnic groups throughout the United States. Two different strategies will be used to localize genes predisposing to kidney disease: a family-based genetic linkage study and a case-control study that utilizes admixture linkage disequilibrium. The center will conduct family-based linkage studies among American Indian populations in the southwestern United States.

ID: NCT00342927
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact: William C Knowler, MD, wknowler@phx.niddk.nih.gov
Location: NIDDK, Phoenix, AZ

Pages

Recommended Reading

Open Clinical Trials for Diabetes Mellitus Harm Reduction (FULL)
Federal Practitioner
CONCLUDE data inconclusive on hypoglycemia risk for degludec vs. glargine
Federal Practitioner
Smoking, inactivity most powerful post-MI lifestyle risk factors
Federal Practitioner
Clinical Pharmacists Improve Patient Outcomes and Expand Access to Care
Federal Practitioner
Certain diabetes drugs may thwart dementia
Federal Practitioner
Dapagliflozin approved for reducing HF hospitalization in diabetes
Federal Practitioner
Severe hypoglycemia, poor glycemic control fuels fracture risk in older diabetic patients
Federal Practitioner
SUSTAIN 10: Weight loss, glycemic control better with semaglutide than liraglutide
Federal Practitioner
A Health Care Provider Intervention to Address Obesity in Patients with Diabetes (FULL)
Federal Practitioner
Evaluating a Program Process Change to Improve Completion of Foot Exams and Amputation Risk Assessments for Veterans with Diabetes (FULL)
Federal Practitioner

Related Articles

  • Pharmacology

    Clinical Pharmacists Improve Patient Outcomes and Expand Access to Care

    The United States Public Health Service National Clinical Pharmacy Specialist Committee issues a report on the impact of pharmacy-managed clinics...